trending Market Intelligence /marketintelligence/en/news-insights/trending/GqlKX5myE9Dby9C1dmWlyw2 content esgSubNav
In This List

Jazz seeks US FDA approval for sleep disorder therapy

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Jazz seeks US FDA approval for sleep disorder therapy

Jazz Pharmaceuticals PLC is seeking the U.S. Food and Drug Administration's approval for Solriamfetol to treat excessive sleepiness in adults with narcolepsy or obstructive sleep apnea.

The company submitted a new drug application for the therapy supported by data from a number of phase 3 clinical trials.

Jazz acquired the rights to develop and commercialize the drug from Aerial BioPharma LLC in 2014.

Narcolepsy is a debilitating neurological disorder characterized by excessive sleepiness, and the inability to regulate sleep-wake cycles normally, while obstructive sleep apnea is a sleep disorder which causes breathing to repeatedly stop and start during sleep.